Page 258 - First Aid for the USMLE Step 1 2020, Thirtieth edition [MedicalBooksVN.com]_Neat
P. 258

214         SECtIoN II    Pathology  ` PATHOLOGY—InfLAMMATIOn                                                                                                           Pathology  ` PATHOLOGY—InfLAMMATIOn





               Erythrocyte           RBCs normally remain separated via ⊝ charges. Products of inflammation (eg, fibrinogen) coat
               sedimentation rate     RBCs Ž  ⊝ charge Ž  RBC aggregation. Denser RBC aggregates fall at a faster rate within a
                                       pipette tube Ž  ESR. Often co-tested with CRP (more specific marker of inflammation).

                                      ESR                                      ESR
                                     Most anemias                              Sickle cell anemia (altered shape)
                                     Infections                                Polycythemia ( RBCs “dilute” aggregation
                                     Inflammation (eg, giant cell [temporal] arteritis,   factors)
                                      polymyalgia rheumatica)                  HF
                                     Cancer (eg, metastases, multiple myeloma)   Microcytosis
                                     Renal disease (end-stage or nephrotic syndrome)  Hypofibrinogenemia
                                     Pregnancy



               Acute inflammation   Transient and early response to injury or infection. Characterized by neutrophils in tissue  A ,
               A                      often with associated edema. Rapid onset (seconds to minutes) and short duration (minutes to
                                      days). Represents a reaction of the innate immune system (ie, less specific response than chronic
                                      inflammation).








                STIMuLI              Infections, trauma, necrosis, foreign bodies.
                MeDIATOrS            Toll-like receptors, arachidonic acid metabolites,  Inflammasome—Cytoplasmic protein complex
                                       neutrophils, eosinophils, antibodies (pre-  that recognizes products of dead cells,
                                       existing), mast cells, basophils, complement,   microbial products, and crystals (eg, uric acid
                                       Hageman factor (factor XII).             crystals) Ž activation of IL-1 and inflammatory
                                                                                response.
                COMPOnenTS               ƒ Vascular: vasodilation (Ž  blood flow and   To bring cells and proteins to site of injury or
                                        stasis) and  endothelial permeability  infection.
                                         ƒ Cellular: extravasation of leukocytes (mainly  Leukocyte extravasation has 4 steps: margination
                                        neutrophils) from postcapillary venules and   and rolling, adhesion, transmigration, and
                                        accumulation in the focus of injury followed   migration (chemoattraction).
                                        by leukocyte activation
                OuTCOMeS                 ƒ Resolution and healing (IL-10, TGF-β)  Macrophages predominate in the late stages of
                                         ƒ Persistent acute inflammation (IL-8)  acute inflammation (peak 2–3 days after onset)
                                         ƒ Abscess (acute inflammation walled off by   and influence outcome by secreting cytokines.
                                        fibrosis)
                                         ƒ Chronic inflammation (antigen presentation
                                        by macrophages and other APCs
                                                         +
                                        Ž activation of CD4  Th cells)
                                         ƒ Scarring




















          FAS1_2019_04-Pathol.indd   214                                                                                11/7/19   4:02 PM
   253   254   255   256   257   258   259   260   261   262   263